Janssen Biotech announced the U.S. FDA has approved Yondelis (trabectedin), a chemotherapy, for the treatment of patients with unresectable (unable to be removed by surgery) or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who previously received chemotherapy that contained anthracycline. LPS and LMS are subtypes of soft tissue sarcoma (STS) and represent more than 35% of all STS cases. YONDELIS is the first treatment to be specifically approved for LPS in the U.S..
According to the National Cancer Institute, STS is a disease in which cancer cells form in the soft tissues of the body, including the muscles, tendons, fat, blood vessels, lymph vessels, nerves and tissues around joints. LPS and LMS are specific types of STS that occur in fat cells (liposarcoma) or smooth muscle cells (leiomyosarcoma). STS can form almost anywhere in the body, but is most common in the head, neck, arms, legs, trunk and abdomen. In 2014, an estimated 12,000 cases of STS were diagnosed in the United States.